Personalis (NASDAQ:PSNL) Stock Price Up 12.5% – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL) was up 12.5% during mid-day trading on Thursday . The stock traded as high as $5.65 and last traded at $5.6710. Approximately 3,865,882 shares traded hands during mid-day trading, an increase of 152% from the average daily volume of 1,535,182 shares. The stock had previously closed at $5.04.

Analyst Ratings Changes

Several analysts recently issued reports on PSNL shares. BTIG Research increased their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Guggenheim increased their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Needham & Company LLC upped their target price on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, Morgan Stanley lowered their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Personalis Stock Up 9.5%

The firm has a 50 day moving average price of $7.14 and a two-hundred day moving average price of $8.32. The company has a market capitalization of $577.82 million, a price-to-earnings ratio of -6.07 and a beta of 2.20.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%. Analysts predict that Personalis, Inc. will post -1.01 earnings per share for the current year.

Institutional Trading of Personalis

Several large investors have recently modified their holdings of the business. Janney Montgomery Scott LLC grew its stake in shares of Personalis by 150.0% during the first quarter. Janney Montgomery Scott LLC now owns 75,000 shares of the company’s stock valued at $478,000 after acquiring an additional 45,000 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after acquiring an additional 7,896,714 shares in the last quarter. Oracle Investment Management Inc. grew its stake in shares of Personalis by 47.9% during the fourth quarter. Oracle Investment Management Inc. now owns 339,343 shares of the company’s stock valued at $2,701,000 after acquiring an additional 109,908 shares in the last quarter. Finally, First Manhattan CO. LLC. acquired a new position in Personalis in the fourth quarter worth about $2,976,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.